Cobra Biologics Announces Development Projects - - BioPharm International

ADVERTISEMENT

Cobra Biologics Announces Development Projects


Cobra Biologics and Novolytics announced that the companies have developed two Staphylococcus aureus-based phage products for Phase I clinical trials with a 100-fold increase in upstream process yields. An existing process was transferred to Cobra’s phage team, which further developed the process in order to increase yields for the two S. aureus-based phage products. The process provides a path to producing suitable GMP material for human clinical trials, according to a Cobra Biologics press release.

In May, Cobra and Recopharma, a biotechnology company developing ophthalmic products, announced that Cobra Biologics will use its maxXpress platform service to deliver a program of vector construction using the UCOE technology, transfectant pool generation, and supply, purification, and protein characterization for a human Fc-fusion protein.

Cobra also announced that it will manufacture Vaccibody’s lead DNA vaccine candidate against HPV-induced malignancies, using its platform process to deliver a program of host strain generation, GMP cell banking, plasmid DNA production, and clinical trials supply.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
EMA Warns of Falsified Herceptin Vials
April 16, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
Author Guidelines

Click here